Takeda Pharmaceutical Company Limited

TSE:4502 Voorraadrapport

Marktkapitalisatie: JP¥6.7t

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Takeda Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

De CEO Takeda Pharmaceutical's is Christophe Weber, benoemd in Jun2014, heeft een ambtstermijn van 10.33 jaar. De totale jaarlijkse vergoeding van { bedraagt ¥ 2.08B, bestaande uit 15.2% salaris en 84.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.05% van de aandelen van het bedrijf, ter waarde ¥ 3.26B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7 jaar en 8.3 jaar.

Belangrijke informatie

Christophe Weber

Algemeen directeur

JP¥2.1b

Totale compensatie

Percentage CEO-salaris15.2%
Dienstverband CEO10.3yrs
Eigendom CEO0.05%
Management gemiddelde ambtstermijn7yrs
Gemiddelde ambtstermijn bestuur8.3yrs

Recente managementupdates

Recent updates

Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00

Sep 24
Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00

Why Investors Shouldn't Be Surprised By Takeda Pharmaceutical Company Limited's (TSE:4502) P/E

Sep 20
Why Investors Shouldn't Be Surprised By Takeda Pharmaceutical Company Limited's (TSE:4502) P/E

Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's

Aug 08
Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's

Earnings Beat: Takeda Pharmaceutical Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 02
Earnings Beat: Takeda Pharmaceutical Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00

Jul 25
Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00

Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's

Jul 11
Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's

Takeda Pharmaceutical Company Limited (TSE:4502) Yearly Results: Here's What Analysts Are Forecasting For This Year

Jun 30
Takeda Pharmaceutical Company Limited (TSE:4502) Yearly Results: Here's What Analysts Are Forecasting For This Year

Takeda Pharmaceutical (TSE:4502) Takes On Some Risk With Its Use Of Debt

Jun 11
Takeda Pharmaceutical (TSE:4502) Takes On Some Risk With Its Use Of Debt

Some Investors May Be Willing To Look Past Takeda Pharmaceutical's (TSE:4502) Soft Earnings

May 21
Some Investors May Be Willing To Look Past Takeda Pharmaceutical's (TSE:4502) Soft Earnings

Takeda Pharmaceutical Company Limited Just Recorded A 6.0% EPS Beat: Here's What Analysts Are Forecasting Next

May 12
Takeda Pharmaceutical Company Limited Just Recorded A 6.0% EPS Beat: Here's What Analysts Are Forecasting Next

Takeda Pharmaceutical (TSE:4502) Is Due To Pay A Dividend Of ¥94.00

Mar 28
Takeda Pharmaceutical (TSE:4502) Is Due To Pay A Dividend Of ¥94.00

Takeda Pharmaceutical (TSE:4502) Has Announced A Dividend Of ¥94.00

Mar 13
Takeda Pharmaceutical (TSE:4502) Has Announced A Dividend Of ¥94.00

Takeda Pharmaceutical (TSE:4502) Will Pay A Dividend Of ¥94.00

Feb 26
Takeda Pharmaceutical (TSE:4502) Will Pay A Dividend Of ¥94.00

Analyse CEO-vergoeding

Hoe is Christophe Weber's beloning veranderd ten opzichte van Takeda Pharmaceutical's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

JP¥150b

Mar 31 2024JP¥2bJP¥317m

JP¥144b

Dec 31 2023n/an/a

JP¥178b

Sep 30 2023n/an/a

JP¥192b

Jun 30 2023n/an/a

JP¥301b

Mar 31 2023JP¥2bJP¥295m

JP¥317b

Dec 31 2022n/an/a

JP¥275b

Sep 30 2022n/an/a

JP¥213b

Jun 30 2022n/an/a

JP¥197b

Mar 31 2022JP¥2bJP¥281m

JP¥230b

Dec 31 2021n/an/a

JP¥439b

Sep 30 2021n/an/a

JP¥473b

Jun 30 2021n/an/a

JP¥431b

Mar 31 2021JP¥2bJP¥267m

JP¥376b

Dec 31 2020n/an/a

JP¥181b

Sep 30 2020n/an/a

JP¥56b

Jun 30 2020n/an/a

JP¥120b

Mar 31 2020JP¥2bJP¥273m

JP¥44b

Dec 31 2019n/an/a

JP¥13b

Sep 30 2019n/an/a

JP¥83b

Jun 30 2019n/an/a

JP¥64b

Mar 31 2019JP¥2bJP¥269m

JP¥135b

Dec 31 2018n/an/a

JP¥110b

Sep 30 2018n/an/a

JP¥141b

Jun 30 2018n/an/a

JP¥120b

Mar 31 2018JP¥1bJP¥254m

JP¥187b

Compensatie versus markt: De totale vergoeding ($USD 14.49M ) Christophe } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de JP markt ($USD 1.46M ).

Compensatie versus inkomsten: De beloning van Christophe is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Christophe Weber (58 yo)

10.3yrs

Tenure

JP¥2,083,000,000

Compensatie

Mr. Christophe Weber has been the President and Chief Executive Officer of Takeda Pharmaceutical Company Limited since June 27, 2014 and April 2015 respectively and served as its Chief Operating Officer fr...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Christophe Weber
President10.3yrsJP¥2.08b0.050%
¥ 3.3b
Seigo Izumo
Chair of Management Boardno datageen gegevensgeen gegevens
Milano Furuta
CFO & Directorless than a yeargeen gegevens0.00083%
¥ 55.2m
Haruhiko Hirate
Member of Management Boardno datageen gegevensgeen gegevens
Salvatore Alesci
Member of Management Board and Head of R&D Global Science & Biomedical Policyno datageen gegevensgeen gegevens
Norimasa Takeda
Chief Accounting Officer & Corporate Controllerno datageen gegevensgeen gegevens
Iwaaki Taniguchi
Senior Vice President of Corporate Finance & Controlling Department11.6yrsgeen gegevensgeen gegevens
Gabriele Ricci
Chief Data & Technology Officer2.7yrsgeen gegevensgeen gegevens
Christopher David O'Reilly
Global Head of Investor Relations & Global Finance4.1yrsgeen gegevensgeen gegevens
Yoshihiro Nakagawa
Global General Counsel10yrsgeen gegevensgeen gegevens
Mwana Lugogo
Chief Ethics & Compliance Officer10yrsgeen gegevensgeen gegevens
Lauren Duprey
Chief Human Resources Officer3.8yrsgeen gegevensgeen gegevens

7.0yrs

Gemiddelde duur

51.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 4502 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Christophe Weber
President10.3yrsJP¥2.08b0.050%
¥ 3.3b
Milano Furuta
CFO & Directorno datageen gegevens0.00083%
¥ 55.2m
Andrew S. Plump
President of Research & Development and Representative Director9.3yrsJP¥972.00m0.0087%
¥ 581.1m
John M. Maraganore
Independent External Director2.3yrsJP¥32.00mgeen gegevens
Steven S. Gillis
Independent External Director5.8yrsJP¥44.00m0.00026%
¥ 17.3m
Emiko Higashi
Independent External Director8.3yrsJP¥49.00m0.00016%
¥ 10.7m
Yoshiaki Fujimori
Independent External Director8.3yrsJP¥40.00m0.00079%
¥ 52.6m
Ian T. Clark
Independent External Director5.8yrsJP¥44.00m0.000070%
¥ 4.7m
Jean-Luc Butel
Independent External Director5.3yrsJP¥38.00mgeen gegevens
Michel Orsinger
Independent External Director8.3yrsJP¥46.00mgeen gegevens
Masami Iijima
Independent External Chair3.3yrsJP¥43.00m0.000020%
¥ 1.3m
Koji Hatsukawa
Independent External Director8.3yrsJP¥43.00m0.00063%
¥ 41.9m

8.3yrs

Gemiddelde duur

66.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 4502 wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.3 jaar).